Pharmalink AB Elects Bengt Julander As Chairman

STOCKHOLM, October 14, 2014 /PRNewswire/ --

Pharmalink AB, a specialty pharma company focused on orphan and niche products, has elected Bengt Julander as Chairman of the Board of Directors. He replaces Anders Wiklund, who joined the board of the Company in 2009 and served as its Chairman from 2011.

Bengt Julander has extensive experience as an entrepreneur and successful businessman in the pharmaceutical and medical technology industries as well as in private equity. He is a member of the boards of several listed and private companies in the life sciences sector, including as Chairman of Medcap AB, Director of Stille AB, Sedana Medical AB, Unimedic AB, Proequo AB and nWise AB. Mr. Julander is a founder of Pharmalink and was Chairman from 1991-2009 after which he remained as a Director on the board of the company.

Dr. Johan Häggblad, Managing Director of Pharmalink, stated: "We thank Anders Wiklund for his considerable contribution to Pharmalink's development. He has been a valued board member and Chairman, and has contributed to the success of the company by providing counsel based on his extensive industry experience."

Dr. Häggblad continued: "Pharmalink has two late-stage products with significant commercial potential. As we progress these programs we anticipate an even greater focus on corporate development. Bengt Julander's election as Chairman will further strengthen our experienced management team's effort to execute on our strategy to grow the business rapidly in the coming years."

Anders Wiklund said: "I am proud to have been involved with Pharmalink over the past five and half years. The Company has made great progress during this time with its two late-stage clinical programs: Busulipo for stem cell replacement cancer therapy and Nefecon for primary IgA nephropathy. I wish Pharmalink every success in the future."

Anders Wiklund remains Senior Advisor to the Company.

About Pharmalink

Pharmalink is a specialty pharma company developing high value products for niche and orphan indications. Pharmalink draws on its extensive experience of pharmaceutical development and marketing to identify and progress products that address significant unmet medical needs. With a successful history in pharmaceutical sales and marketing, and highly experienced, dynamic management team, Pharmalink is focused on the development and commercialization of valuable, de-risked projects. It has two late-stage clinical phase products under development, Nefecon® and Busulipo™. Pharmalink is actively seeking opportunities to acquire or in-license product opportunities in niche and hospital care indications. Visit http://www.pharmalink.se for further information. 

Suggested Articles

Gilead Chief Scientific Officer and R&D chief John McHutchison, M.D., is leaving one year after he replaced R&D lead Norbert Bischofberger, Ph.D.

Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.

Inovio Pharmaceuticals is cutting 28% of its workforce and swinging the ax to a bladder cancer test.